- Retatrutide is studied as a multi-receptor peptide in controlled research environments where investigators are evaluating the interaction between GLP-1 receptor signaling, GIP receptor activity, glucagon receptor pathways, metabolic adaptation, insulinotropic pathway behavior, appetite-associated signaling models, and energy expenditure biology
At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide
Potential candidates may include: Individuals close to their goal weight Patients focused on weight maintenance Those who experienced side effects on higher doses Patients interested in a gradual, medically supervised approach A comprehensive medical consultation is the best way to determine whether microdosing is appropriate
PlexusDx offers GLP-Squared injections at $289/mo month-to-month, or from $249/mo on the 3-month plan for patients ready to explore multi-pathway therapy
This 3-in-1 approach differentiates retatrutide from existing obesity drugs, and explains why many researchers believe it will outperform todays GLP-1-dominant therapies
M.StaggS.et al (2021)
